Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms FITZROY
  • Sponsors Galapagos NV
  • Most Recent Events

    • 01 Aug 2022 Results assessing effects of JAK1-Preferential Inhibitor Filgotinib on circulating biomarkers and whole blood Genes/Pathways using data from this study published in the Inflammatory Bowel Diseases
    • 19 May 2020 Results, analysis of baseline correlation of whole blood transcriptome pathway activities with clinical disease indexes and circulating cytokines, published in Gastroenterology in conjunction with Digestive Disease Week 2020
    • 19 May 2020 Results of poct-hoc analysis assessing the effect of FIL on molecular markers of JAK1-related signalling (STAT1 & STAT3 phosphorylation) within epithelium and non-epithelium regions of intestinal mucosa and explore their correlation to histologic and endoscopic indices published at the Digestive Disease Week 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top